Lung Cancer
News from the FDA/CDC
FDA approves brigatinib and companion diagnostic for NSCLC
Feature
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
From the Journals
Low-dose erlotinib seems feasible for frail, elderly patients with NSCLC
The disease control rate was 90%, the median progression-free survival was 9.3 months, and few patients required treatment modifications.
News from the FDA/CDC
FDA expands approval of atezolizumab in NSCLC
–s...
News from the FDA/CDC
FDA approves chemo-free combo for lung cancer
Conference Coverage
Quitting smoking just 2 years before lung cancer diagnosis may improve survival
Conference Coverage
MRD surveillance can detect relapse before imaging in early-stage NSCLC
Relapse occurred in 9 of 10 patients who were positive for minimal residual disease but had no evidence of relapse on imaging.
News from the FDA/CDC
FDA approves selpercatinib for lung and thyroid RET tumors
News from the FDA/CDC
NSCLC: FDA approves capmatinib and companion assay
Capmatinib is the first FDA-approved treatment for NSCLC with MET exon 14 skipping mutations.
Conference Coverage
Capmatinib shows impressive results in METex14-mutated NSCLC
Capmatinib produced durable responses, even in patients with brain metastases.